Last updated: 12 June 2024 at 8:20pm EST

Mark Blumenkranz Net Worth




The estimated Net Worth of Mark S. Blumenkranz is at least $586 Thousand dollars as of 11 May 2023. Mark Blumenkranz owns over 14,588 units of 1Life Healthcare stock worth over $528,489 and over the last 9 years he sold ONEM stock worth over $0. In addition, he makes $57,099 as Independent Director at 1Life Healthcare.

Mark Blumenkranz ONEM stock SEC Form 4 insiders trading

Mark has made over 5 trades of the 1Life Healthcare stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 14,588 units of ONEM stock worth $240,264 on 11 May 2023.

The largest trade he's ever made was exercising 14,588 units of 1Life Healthcare stock on 11 May 2023 worth over $240,264. On average, Mark trades about 2,035 units every 37 days since 2015. As of 11 May 2023 he still owns at least 32,088 units of 1Life Healthcare stock.

You can see the complete history of Mark Blumenkranz stock trades at the bottom of the page.





Mark Blumenkranz biography

Dr. Mark S. Blumenkranz M.D. serves as Independent Director of the Company. Since October 2015, Dr. Blumenkranz has served as the managing director of Lagunita Biosciences LLC, a healthcare investment company. Since September 2019, Dr. Blumenkranz has served as the chief executive officer of Kedalion Therapeutics Inc., an ophthalmic drug development company. From 1997 to August 2015, he served as the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University School of Medicine and as the inaugural director of the Byers Eye Institute, a nationally-recognized eye care center. From January 2015 to August 2015, Dr. Blumenkranz served on the board of directors of Presbia PLC, a medical device company. From July 2006 to February 2017, Dr. Blumenkranz served on the board of directors of Adverum Biotechnologies Inc., a biotechnology company. He also serves on the board of directors of several private biotechnology and medical device companies. Dr. Blumenkranz earned an A.B. in Biology, an M.M.S. in Biochemical Pharmacology and an M.D. from Brown University. He received his surgical internship and ophthalmology residency training at the Stanford University School of Medicine and his fellowship training in vitreoretinal surgery at the Bascom Palmer Eye Institute at the University of Miami School of Medicine. Blumenkranz is qualified to serve as a member of our board of directors because of his experience as a director and founder of several biotechnology companies as well as his significant expertise in medical practice.

What is the salary of Mark Blumenkranz?

As the Independent Director of 1Life Healthcare, the total compensation of Mark Blumenkranz at 1Life Healthcare is $57,099. There are 8 executives at 1Life Healthcare getting paid more, with Amir Rubin having the highest compensation of $13,920,200.



How old is Mark Blumenkranz?

Mark Blumenkranz is 68, he's been the Independent Director of 1Life Healthcare since 2019. There are no older and 16 younger executives at 1Life Healthcare.

What's Mark Blumenkranz's mailing address?

Mark's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.

Insiders trading at 1Life Healthcare

Over the last 5 years, insiders at 1Life Healthcare have traded over $573,693,882 worth of 1Life Healthcare stock. The most active insiders traders include Group Management L.L.C.Carl..., Amir Dan Rubin, and Scott C Taylor. On average, 1Life Healthcare executives and independent directors trade stock every 10 days with the average trade being worth of $4,338,939. The most recent stock trade was executed by Bjorn B Thaler on 15 February 2023, trading 13,829 units of ONEM stock currently worth $227,764.



What does 1Life Healthcare do?

1Life Healthcare, Inc. operates a membership-based primary care platform under the One Medical brand. The company has developed a healthcare membership model based on direct consumer enrollment, as well as third-party sponsorship. Its membership model includes seamless access to 24/7 digital health services paired with inviting in-office care routinely covered under health insurance programs. The company also offers administrative and managerial services pursuant to contracts with physician-owned professional corporations or One Medical Entities. As of December 31, 2021, it had 703,000 consumer and enterprise members, and 33,000 At-Risk members; 182 medical offices in 25 markets; and 8,500 enterprise clients in the United States. The company was incorporated in 2002 and is headquartered in San Francisco, California.



What does 1Life Healthcare's logo look like?

1Life Healthcare, Inc. logo

Complete history of Mark Blumenkranz stock trades at Kala Bio, IVERIC bio Inc, and 1Life Healthcare

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
11 May 2023 Mark S. Blumenkranz
Director
Option 14,588 $37.36 $545,008
11 May 2023
32,088
15 Jul 2022 Mark S. Blumenkranz
Director
Option 5,000 $11.70 $58,500
15 Jul 2022
17,500
11 May 2022 Mark S. Blumenkranz
Director
Option 7,500 $10.13 $75,975
11 May 2022
12,500
15 Jul 2021 Mark S. Blumenkranz
Director
Option 5,000 $9.79 $48,950
15 Jul 2021
5,000
2 Jun 2022 Mark S. Blumenkranz
Option 4,534 $8.85 $40,126
2 Jun 2022
4,534


1Life Healthcare executives and stock owners

1Life Healthcare executives and other stock owners filed with the SEC include: